KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biolife Solutions (BLFS) Non-Current Deffered Revenue (2016 - 2021)

Biolife Solutions (BLFS) has disclosed Non-Current Deffered Revenue for 9 consecutive years, with $349000.0 as the latest value for Q4 2018.

  • On a quarterly basis, Non-Current Deffered Revenue fell 29.07% to $349000.0 in Q4 2018 year-over-year; TTM through Dec 2018 was $349000.0, a 29.07% decrease, with the full-year FY2018 number at $349000.0, down 29.07% from a year prior.
  • Non-Current Deffered Revenue was $349000.0 for Q4 2018 at Biolife Solutions, down from $386113.0 in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $914674.0 in Q4 2015 to a low of -$18007.0 in Q3 2014.
  • A 5-year average of $325790.0 and a median of $349000.0 in 2018 define the central range for Non-Current Deffered Revenue.
  • Peak YoY movement for Non-Current Deffered Revenue: plummeted 105.09% in 2014, then skyrocketed 5306.31% in 2017.
  • Biolife Solutions' Non-Current Deffered Revenue stood at -$18007.0 in 2014, then soared by 5179.55% to $914674.0 in 2015, then decreased by 10.82% to $815666.0 in 2016, then tumbled by 39.68% to $492000.0 in 2017, then fell by 29.07% to $349000.0 in 2018.
  • Per Business Quant, the three most recent readings for BLFS's Non-Current Deffered Revenue are $349000.0 (Q4 2018), $386113.0 (Q3 2018), and $422828.0 (Q2 2018).